Mylan Launches First Generic Version Of Vivelle-DOT - Quick Facts

(RTTNews) - Mylan Inc. (MYL) Monday announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), which is the generic version of Novartis' Vivelle-DOT.

Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of moderate to severe vasomotor symptoms and moderate to severe symptoms of vulvar and vaginal atrophy due to menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; and the prevention of postmenopausal osteoporosis.

Mylan CEO Heather Bresch said, "The approval of Mylan's Estradiol Transdermal System USP represents our seventh U.S. transdermal product launch and strengthens the company's growing portfolio of women's health products."

Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day (Twice Weekly), had U.S. sales of around $262.5 million for the 12 months ended September 30, according to IMS Health.

Currently, Mylan has 285 ANDAs pending FDA approval representing $111.3 billion in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3 billion in annual brand sales, for the 12 months ended June 30.